ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 85 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q1 2021. The put-call ratio across all filers is 1.06 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,322,227 | -15.7% | 17,079,778 | 0.0% | 1.03% | -14.7% |
| Q2 2023 | $15,798,795 | -15.1% | 17,079,778 | -0.0% | 1.21% | -6.3% |
| Q1 2023 | $18,616,958 | -25.3% | 17,079,779 | 0.0% | 1.29% | -8.1% |
| Q4 2022 | $24,936,476 | +35.8% | 17,079,779 | -0.0% | 1.40% | +52.8% |
| Q3 2022 | $18,364,000 | -36.8% | 17,082,612 | 0.0% | 0.92% | -38.5% |
| Q2 2022 | $29,040,000 | -17.5% | 17,082,612 | +0.0% | 1.49% | +46.9% |
| Q1 2022 | $35,190,000 | -45.1% | 17,082,611 | 0.0% | 1.02% | -21.5% |
| Q4 2021 | $64,060,000 | -27.5% | 17,082,611 | 0.0% | 1.30% | +23.5% |
| Q3 2021 | $88,317,000 | +21.4% | 17,082,611 | 0.0% | 1.05% | +10.7% |
| Q2 2021 | $72,772,000 | -19.8% | 17,082,611 | 0.0% | 0.95% | -53.4% |
| Q1 2021 | $90,709,000 | -1.5% | 17,082,611 | 0.0% | 2.04% | -16.2% |
| Q4 2020 | $92,075,000 | -32.5% | 17,082,611 | 0.0% | 2.43% | -57.9% |
| Q3 2020 | $136,319,000 | -20.3% | 17,082,611 | 0.0% | 5.77% | -16.0% |
| Q2 2020 | $170,997,000 | +268.0% | 17,082,611 | 0.0% | 6.87% | +183.1% |
| Q1 2020 | $46,465,000 | +144.6% | 17,082,611 | +7.9% | 2.43% | +170.4% |
| Q4 2019 | $18,999,000 | -20.5% | 15,832,611 | 0.0% | 0.90% | -54.6% |
| Q3 2019 | $23,907,000 | -62.4% | 15,832,611 | 0.0% | 1.98% | -55.6% |
| Q2 2019 | $63,647,000 | -6.5% | 15,832,611 | 0.0% | 4.46% | +26.1% |
| Q1 2019 | $68,080,000 | -25.2% | 15,832,611 | 0.0% | 3.54% | -2.1% |
| Q4 2018 | $91,038,000 | -57.6% | 15,832,611 | 0.0% | 3.61% | -61.0% |
| Q3 2018 | $214,690,000 | +35.7% | 15,832,611 | +18.8% | 9.26% | +25.0% |
| Q2 2018 | $158,258,000 | +5.7% | 13,332,611 | 0.0% | 7.41% | +11.3% |
| Q1 2018 | $149,725,000 | +86.4% | 13,332,611 | +10.9% | 6.66% | +100.1% |
| Q4 2017 | $80,334,000 | -18.4% | 12,025,999 | 0.0% | 3.33% | -3.5% |
| Q3 2017 | $98,493,000 | +82.4% | 12,025,999 | 0.0% | 3.45% | +75.6% |
| Q2 2017 | $53,997,000 | -18.5% | 12,025,999 | 0.0% | 1.96% | -14.8% |
| Q1 2017 | $66,263,000 | +65.6% | 12,025,999 | +21.7% | 2.30% | +44.9% |
| Q4 2016 | $40,018,000 | -42.6% | 9,880,999 | 0.0% | 1.59% | -49.1% |
| Q3 2016 | $69,661,000 | -13.5% | 9,880,999 | 0.0% | 3.13% | -25.2% |
| Q2 2016 | $80,530,000 | +0.2% | 9,880,999 | 0.0% | 4.18% | -21.6% |
| Q1 2016 | $80,333,000 | – | 9,880,999 | – | 5.34% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Syncona Portfolio Ltd | 1,377,294 | $1,501,250 | 2.44% |
| NEA Management Company, LLC | 17,079,779 | $18,616,958 | 1.29% |
| Endurant Capital Management LP | 1,660,835 | $1,810,310 | 0.93% |
| Matrix Capital Management Company, LP | 38,974,185 | $42,481,862 | 0.58% |
| Long Focus Capital Management, LLC | 5,435,439 | $5,924,629 | 0.34% |
| PFM Health Sciences, LP | 5,992,571 | $6,531,902 | 0.29% |
| Key Client Fiduciary Advisors, LLC | 321,155 | $350,059 | 0.22% |
| DAFNA Capital Management LLC | 351,064 | $382,660 | 0.12% |
| Rock Springs Capital Management LP | 2,787,845 | $3,038,751 | 0.07% |
| Baker Brothers Advisors | 9,830,877 | $10,715,656 | 0.06% |